NasdaqGS - Delayed Quote • USD
Neurocrine Biosciences, Inc. (NBIX)
At close: April 25 at 4:00 PM EDT
After hours: April 25 at 5:45 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 18 | 17 | 18 | 18 |
| Avg. Estimate | 1.01 | 1.18 | 4.77 | 6.41 |
| Low Estimate | 0.18 | 0.89 | 3.82 | 4.58 |
| High Estimate | 1.77 | 1.67 | 5.72 | 8.58 |
| Year Ago EPS | -0.79 | 0.95 | 2.47 | 4.77 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 23 | 21 | 25 | 26 |
| Avg. Estimate | 511.54M | 543.98M | 2.21B | 2.58B |
| Low Estimate | 491.5M | 529M | 2.14B | 2.26B |
| High Estimate | 528M | 567M | 2.3B | 3.78B |
| Year Ago Sales | 409.26M | 447.31M | 1.89B | 2.21B |
| Sales Growth (year/est) | 25.00% | 21.60% | 17.00% | 16.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.13 | 0.78 | 0.97 | 1.14 |
| EPS Actual | -0.79 | 0.95 | 0.82 | 1.44 |
| Difference | -0.92 | 0.17 | -0.15 | 0.3 |
| Surprise % | -707.70% | 21.80% | -15.50% | 26.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 1.01 | 1.18 | 4.77 | 6.41 |
| 7 Days Ago | 0.99 | 1.18 | 4.78 | 6.4 |
| 30 Days Ago | 1 | 1.19 | 4.8 | 6.29 |
| 60 Days Ago | 1 | 1.19 | 4.79 | 6.3 |
| 90 Days Ago | 1.07 | 1.18 | 4.76 | 6.45 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 2 | 2 | 2 | 2 |
| Up Last 30 Days | 6 | 5 | 5 | 7 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 4 | 3 | 3 | 4 |
Growth Estimates
| CURRENCY IN USD | NBIX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 227.80% | -- | -- | 2.60% |
| Next Qtr. | 24.20% | -- | -- | 13.40% |
| Current Year | 93.10% | -- | -- | 5.20% |
| Next Year | 34.40% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 18.00% | -- | -- | 11.11% |
| Past 5 Years (per annum) | 22.55% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Upgrade | Wells Fargo: Equal-Weight to Overweight | 4/24/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 4/24/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/24/2024 |
| Reiterates | Needham: Hold | 4/23/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 4/17/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/10/2024 |
Related Tickers
ITCI Intra-Cellular Therapies, Inc.
72.13
-1.35%
ALKS Alkermes plc
24.44
-0.85%
AQST Aquestive Therapeutics, Inc.
3.9300
+0.77%
IRWD Ironwood Pharmaceuticals, Inc.
8.08
-0.25%
TAK Takeda Pharmaceutical Company Limited
13.07
-1.21%
LNTH Lantheus Holdings, Inc.
65.20
-0.02%
AVDL Avadel Pharmaceuticals plc
17.82
+0.91%
DVAX Dynavax Technologies Corporation
11.17
-2.19%
SUPN Supernus Pharmaceuticals, Inc.
29.31
-3.14%
AMRX Amneal Pharmaceuticals, Inc.
5.90
-2.48%